This is a summary of the European public assessment report (EPAR) for Kinzalmono. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Kinzalmono.
Therapeutic Indication
### Therapeutic indication **Hypertension** Treatment of essential hypertension in adults. **Cardiovascular prevention** Reduction of cardiovascular morbidity in patients with: - manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; - type-2 diabetes mellitus with documented target-organ damage.
Therapeutic Area (MeSH)
ATC Code
C09CA07
ATC Item
telmisartan
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
INN / Common Names
EMA Name
Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)
Medicine Name
Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)
Aliases
N/ANo risk management plan link.
